UB enters multinational partnership for cannabinoid R&D

UB’s Center for Integrated Global Biomedical Sciences (CIGBS) is partnering with Pure Jamaican/Seven-10 Pharmaceuticals and DENT Neurologic Institute in Western New York to research safe and therapeutic uses of cannabinoids — the substances found in the cannabis plant, such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

This new scientific initiative creates a hub of pharmaceutical research in Kingston and Montego Bay, Jamaica, and builds on the established global cannabinoids research program led by Gene Morse, SUNY Distinguished Professor in the School of Pharmacy and Pharmaceutical Sciences, director of the CIGBS and co-director of the SUNY Global Health Institute.

The upcoming work will include Buffalo-based pharmacology laboratory research and clinical trial design, study guidance and enrollment, depending on the stage of drug development.

“Cannabinoid research requires a consistent drug product, and it’s mandatory for research integrity,” Morse explains. “This collaboration establishes a framework for creating multinational clinical trials paired with a consistent supply of novel pharmaceutical-grade botanical medicines produced in a GMP (good manufacturing practices)-certified facility in Jamaica.”

When a facility is GMP-compliant, its manufacturing processes are clearly defined, controlled and validated to produce consistent, high-quality products.

The CIGBS, which includes UB researchers in pharmacy, dentistry, public health, chemistry, informatics and medicine, is working to create drug assays that can measure cannabinoids and how they are metabolized in both animals and humans. Blood samples from these animal and human studies help the researchers understand how the cannabinoids are absorbed, distributed and eliminated. This data is then used to determine the proper therapeutic dosing regimens.

“Although cannabinoids are available for prescription and non-prescription use, research is needed to determine how to use them safely and effectively,” Morse says. “Clinical research is ongoing in the management of chronic non-cancer pain, opioid use disorders, anxiety, seizures, nausea and vomiting related to chemotherapy, post-traumatic stress disorder, multiple sclerosis and sleep problems.

“At a time when more than half of the states in the country have legalized marijuana and many people use CBD to treat a number of health issues, it’s crucial that we work to develop the safest therapeutic models of these drugs,” Morse adds. “We are excited to work with the Pure Jamaican, Seven-10 and DENT teams to deliver major changes in global health and contribute to sustainable business development in low- and middle-income countries.”

The research will help build academic infrastructures both in Western New York and Jamaica, provide mentoring opportunities for UB researchers and help stimulate economic impact.

“Seven-10 Pharmaceuticals, which is part of the Pure Jamaican group of companies, has an outstanding team of scientists and has established itself as a leader,” Morse notes. “They are not only making strides in the production of pharma-grade cannabinoid medicines, but also in the export of products containing THC into the United States, Brazil and other major markets.”

Scott Cathcart, CEO of Pure Jamaican and Seven-10 Pharmaceuticals, says the companies “are thrilled to partner with the DENT Neurologic Institute and the CIGBS, each of which is a highly respected leader in cannabinoid sciences research. Together, we will help accelerate multinational research to support therapeutic use of new, plant-based medicines and innovative consumer products.”

The collaboration also will enhance programs that the CIGBS has developed in conjunction with DENT — home to one of the nation’s largest and most comprehensive physician-directed medical cannabis programs with more than 15,000 active patients — along with the University of the West Indies, Mona Campus in Jamaica and the University of Zimbabwe Center of Excellence in Pharmaceutical Innovation.

“The DENT Neurologic Institute provides a unique ecosystem for pioneering research in cannabinoid pharmacotherapy, offering the infrastructure and expertise to conduct studies ranging from healthy volunteer trials to targeted therapeutic protocols,” says Laszlo Mechtler, chief medical officer of DENT Neurologic Institute and medical director of its Cannabis Clinic and Research Center.

“With decades of experience, we ensure a safe and effective framework for advancing cannabinoid-based treatments and engaging our community in groundbreaking research.”

He notes that the expanded partnership marks a significant milestone in DENT’s mission to legitimize cannabinoid-based therapies, not only in Western New York and the U.S. but internationally.

“Home to the largest cannabis treatment and research program of its kind, we offer unparalleled insights into the therapeutic potential of cannabinoids,” Mechtler adds. “Our successful track record, including multiple research initiatives with CIGBS, reinforces the strength of this collaboration. We look forward to expanding our partnership, further advancing scientific discovery and shaping the future of cannabinoid-based medicine.”